Ampio soars on FDA nod to study lead drug as COVID-19 respiratory distress therapy

Ampio Pharmaceuticals

21/09/2020 14:54

** Drug developer's  AMPE.A  shares jump ~33% to $1.25
    ** Company receives U.S. FDA approval to begin an
early-stage trial for its experimental lead drug, Ampion, as an
inhalation therapy for respiratory distress due to COVID-19
infection  urn:newsml:reuters.com:*:nPn4RZCv6a
    ** Study will enroll 40 patients, who will receive Ampion by
inhalation through a hand-held nebulizer
    ** Shares jumped as much as ~13% on Sept. 9, after company
said COVID-19 patients treated with Ampion intravenously showed
greater improvement compared with patients treated with
standard-of-care, in an early-stage trial  urn:newsml:reuters.com:*:nL4N2G62WS
    ** Including session's gain, AMPE stock up ~116% this year

 (Reporting By Mrinalika Roy in Bengaluru)
 ((mrinalika.roy@thomsonreuters.com; within U.S. +1 646 223
8780, outside U.S. +91 806749 8325;))